Perspectives on Clinical Adoption Barriers to Blood-Based Multi-Cancer Early Detection Tests across Stakeholders

Area of Science:

• Oncology
• Preventive Medicine
• Health Services Research

Background:

• Current cancer screening guidelines from the United States Preventive Services Task Force (USPSTF) focus on specific cancers, missing opportunities for early detection in other indications.
• A significant proportion of cancer cases are diagnosed at advanced stages, contributing to higher mortality rates.
• Blood-based multi-cancer early detection (MCED) tests offer a novel approach to screen for multiple cancer types simultaneously, including those not routinely screened.

Purpose of the Study:

• To assess current cancer screening practices among healthcare providers (HCPs), payers, and patients in the U.S.
• To identify perceived barriers and facilitators for the adoption of blood-based MCED tests.
• To understand the value proposition and anticipated utilization of MCED tests within the U.S. health system.

Main Methods:

• A survey was conducted among U.S. healthcare providers, payers, and patients.
• The survey focused on current cancer screening test utilization and perceptions of blood-based MCED tests.
• Data analysis aimed to identify trends in adoption and barriers to widespread use.

Main Results:

• The healthcare community generally favors the adoption of blood-based MCED tests, recognizing their value proposition.
• Current limited utilization is attributed to concerns regarding clinical accuracy and utility data.
• High out-of-pocket patient costs and inadequate payer coverage were identified as significant adoption hurdles.

Conclusions:

• Widespread adoption of blood-based MCED tests requires addressing current barriers.
• Increased investment in generating robust clinical data is crucial.
• Enhanced education for healthcare providers and improved logistical support are essential for successful implementation.